Eitan Machover - Medigus Independent Director
MDGS Stock | USD 2.84 0.16 5.97% |
Director
Mr. Eitan Machover was appointed as Independent Director of the Company., effective September 29, 2016. Mr. Machover has more than 30 years of leadership experience in healthcare, having held various business development and MA positions at GE Capital in the U.S., Europe and Asia. He headed business development activities at GE Healthcare in Europe, where he oversaw largescale acquisitions. In addition, he led integrations into GE Israeli operations and was later named the National Executive for General Electric Israel, overseeing all of GE activities in the country. Since then, Mr. Machover coestablished MediTech Advisors, where he managed two U.S. based medical device venture funds, and also served as CEO of Wellsense, Inc. a U.S. medical device company. Currently, he is the principal and owner of EM Advisory Service, Ltd. an Israelbased executive search firm since 2016.
Age | 55 |
Tenure | 8 years |
Professional Marks | MBA |
Address | 10 Hanechoshet, Tel Aviv, Israel, 6971072 |
Phone | 972 73 370 4691 |
Web | https://www.medigus.com |
Medigus Management Efficiency
The company has return on total asset (ROA) of (0.0663) % which means that it has lost $0.0663 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3072) %, meaning that it created substantial loss on money invested by shareholders. Medigus' management efficiency ratios could be used to measure how well Medigus manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to drop to -0.22 in 2024. Return On Assets is likely to drop to -0.1 in 2024. At this time, Medigus' Asset Turnover is comparatively stable compared to the past year.Similar Executives
Showing other executives | DIRECTOR Age | ||
Mary Hoeltzel | Cigna Corp | N/A | |
Peter Neupert | Laboratory | 65 | |
Michael Fernandez | Mednax Inc | 66 | |
Manuel Kadre | Mednax Inc | 54 | |
William Zollars | Cigna Corp | 70 | |
Roman Martinez | Cigna Corp | 71 | |
Gary Gilliland | Laboratory | 63 | |
Dipchand Nishar | Guardant Health | N/A | |
Robert Mittelstaedt | Laboratory | 74 | |
JeanLuc Belingard | Laboratory | 72 | |
Garheng Kong | Laboratory | 45 | |
Enrique Sosa | Mednax Inc | 79 | |
Stanley Meresman | Guardant Health | 71 | |
Donna Zarcone | Cigna Corp | 63 | |
Kerrii Anderson | Laboratory | 63 | |
John Partridge | Cigna Corp | 71 | |
Jeffrey Davis | Laboratory | 57 | |
Sanders Williams | Laboratory | 69 | |
Jane Henney | Cigna Corp | 69 | |
Samir Kaul | Guardant Health | 44 | |
Eric Wiseman | Cigna Corp | 65 |
Management Performance
Return On Equity | -0.31 | ||||
Return On Asset | -0.0663 |
Medigus Ltd ADR Leadership Team
Elected by the shareholders, the Medigus' board of directors comprises two types of representatives: Medigus inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Medigus. The board's role is to monitor Medigus' management team and ensure that shareholders' interests are well served. Medigus' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Medigus' outside directors are responsible for providing unbiased perspectives on the board's policies.
Ilan Oren, Executive Officer | ||
Efrat Venkert, External Director | ||
Anat Naschitz, Director | ||
Yaron Silberman, Chief Ltd | ||
Ori Hershkovitz, External Director | ||
Yair Rabinovitch, Director | ||
Menashe Sonnenschein, Vice President - Operations | ||
Gilad Mamlok, CFO | ||
Christopher Rowland, CEO and Director | ||
Eitan Machover, Independent Director | ||
Minelu Sonnenschein, VP of Operations | ||
Oded Yatzkan, Director of Fin. and Accounting and VP | ||
Nissim Darvish, Chairman of the Board | ||
Jeremy Starkweather, Director of Sales, Director of Marketing-United States | ||
Yuval Yanai, Director | ||
Aviel Shapira, Medical Director | ||
Yair Rabinowitch, Director | ||
Liron Carmel, Chief Officer | ||
Erez Haimovitz, Director | ||
Tali Dinar, Chief Officer | ||
Doron Birger, Director | ||
Tatyana Yossef, Controller | ||
Yaron Zilberman, Vice President - Sales and Marketing |
Medigus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Medigus a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.31 | ||||
Return On Asset | -0.0663 | ||||
Profit Margin | (0.13) % | ||||
Operating Margin | (0.09) % | ||||
Current Valuation | 2.05 M | ||||
Shares Outstanding | 1.89 M | ||||
Shares Owned By Institutions | 0.28 % | ||||
Number Of Shares Shorted | 5.05 K | ||||
Price To Earning | 33.86 X | ||||
Price To Book | 0.16 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medigus Ltd ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Medigus Ltd ADR information on this page should be used as a complementary analysis to other Medigus' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Complementary Tools for Medigus Stock analysis
When running Medigus' price analysis, check to measure Medigus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medigus is operating at the current time. Most of Medigus' value examination focuses on studying past and present price action to predict the probability of Medigus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medigus' price. Additionally, you may evaluate how the addition of Medigus to your portfolios can decrease your overall portfolio volatility.
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |
Is Medigus' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Medigus. If investors know Medigus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Medigus listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.70) | Revenue Per Share 67.313 | Quarterly Revenue Growth 0.527 | Return On Assets (0.07) | Return On Equity (0.31) |
The market value of Medigus Ltd ADR is measured differently than its book value, which is the value of Medigus that is recorded on the company's balance sheet. Investors also form their own opinion of Medigus' value that differs from its market value or its book value, called intrinsic value, which is Medigus' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Medigus' market value can be influenced by many factors that don't directly affect Medigus' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Medigus' value and its price as these two are different measures arrived at by different means. Investors typically determine if Medigus is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Medigus' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.